Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fondaparinux Sodium

FDA-approved product (solution, subcutaneous), marketed as Arixtra, Fondaparinux Sodium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Fondaparinux Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Deep vein thrombosis
  • Intermediate coronary syndrome
  • Myocardial infarction
  • Pulmonary embolism
  • Recurrent thrombophlebitis
  • Venous thrombosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antithrombotic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fondaparinux Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fondaparinux Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)

    NCT00060554 · start 2003-04

    Registered record
    Registry ID
    NCT00060554
    Conditions
    Myocardial Infarction; Coronary Disease
    Interventions
    fondaparinux sodium; heparin; percutaneous coronary intervention (PCI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2003-04
    Completion
    Not recorded
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction; Coronary Disease
    Interventionfondaparinux sodium; heparin; percutaneous coronary intervention (PCI)
    PhasePhase 2
    Registry statusWithdrawn

  • Michelangelo - Oasis 5

    NCT00139815 · start 2003-04

    Registered record
    Registry ID
    NCT00139815
    Conditions
    Thromboembolism
    Interventions
    Fondaparinux; enoxaparin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-04
    Completion
    2005-12
    Enrolment
    20,078

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThromboembolism
    InterventionFondaparinux; enoxaparin
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO).

    NCT00038961 · start 2001-11

    Registered record
    Registry ID
    NCT00038961
    Conditions
    Thromboembolism
    Interventions
    fondaparinux sodium; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-11
    Completion
    2004-10
    Enrolment
    1,309

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThromboembolism
    Interventionfondaparinux sodium; placebo
    PhasePhase 3
    Registry statusCompleted

  • Prevention of Thrombosis Recurrence in Patients With Low Circulating Levels of Antithrombin.

    NCT01382550 · start 1993-03

    Registered record
    Registry ID
    NCT01382550
    Conditions
    Venous Thrombosis
    Interventions
    long-lasting OAT or 12-month OAT
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    1993-03
    Completion
    Not recorded
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thrombosis
    Interventionlong-lasting OAT or 12-month OAT
    PhaseNot recorded
    Registry statusUnknown

  • Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery: The Fonda CABG Study

    NCT00474591

    Registered record
    Registry ID
    NCT00474591
    Conditions
    Coronary Bypass Graft Failure/Occlusion
    Interventions
    Fondaparinux
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Bypass Graft Failure/Occlusion
    InterventionFondaparinux
    PhasePhase 3
    Registry statusUnknown